drugset / Trial / NCT07543536
Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
RandomizedParallel-groupTriple-blindTreatment
Summary
This study aims to evaluate whether the combination of Megestrol Acetate at the initiation of Trastuzumab Deruxtecan (T-DXd) treatment can effectively prevent and alleviate T-DXd-related fatigue, thereby improving the quality of life for advanced breast cancer patients.
Timeline
- Start
- 2026-05-01
- Primary completion
- 2029-04-01
- Completion
- 2031-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Megestrol Acetate | Other / unclassified | 160 mg | Oral |
| Background | Trastuzumab deruxtecan | Monoclonal antibody | 5.4 mg/kg | Intravenous |